holidayexpt.com → get → infection ear tract → what converts testosterone to dht
Posted on by Ethan Washington

What Converts Testosterone to DHT

Microscopic view of human prostate tissue showing enzyme activity related to DHT production

The enzyme 5-alpha reductase converts testosterone into dihydrotestosterone (DHT), a more potent androgen. This reaction occurs primarily in androgen-responsive tissues such as the prostate, scalp, and skin, where DHT binds more tightly to androgen receptors than testosterone does.

Testosterone circulates in the bloodstream at levels typically between 300 and 1,000 ng/dL in adult males. Once it reaches target tissues, 5-alpha reductase reduces the double bond between carbons 4 and 5 in testosterone's A-ring, forming DHT. This structural change increases DHT's affinity for the androgen receptor by approximately 2.5 times compared to testosterone.

According to the Endocrine Society's 2020 guidelines on androgen metabolism, 5-alpha reductase exists in two isoforms: Type 1, which is expressed in sebaceous glands and liver, and Type 2, which dominates in reproductive tissues like the prostate and seminal vesicles. Type 2 is the primary target of pharmaceutical inhibitors used to treat benign prostatic hyperplasia (BPH) and male pattern baldness.

How the Conversion Works

5-alpha reductase catalyzes a two-step reduction process using NADPH as a cofactor. The enzyme binds testosterone in the cytoplasm of target cells, then transfers two hydrogen atoms to the 4-5 double bond, resulting in saturation. This creates DHT, which has a higher binding affinity for androgen receptors due to its rigid structure and enhanced membrane permeability.

In the prostate gland, DHT levels can exceed testosterone concentrations by up to 10-fold. This local amplification of androgen signaling drives cellular proliferation and contributes to both normal prostate function and pathological enlargement. The enzyme is most active during fetal development and puberty, when androgen exposure shapes genital differentiation and secondary sexual characteristics.

A 2018 study published in *The Journal of Clinical Endocrinology & Metabolism* measured DHT levels in men with and without alopecia. Men with moderate to severe hair loss had average serum DHT levels 18% higher than controls, though individual variation remains high., DHT concentration in scalp tissue was 3.6 times greater than in serum, indicating localized synthesis rather than systemic distribution.

Types of 5-Alpha Reductase and Their Roles

Two distinct isoenzymes mediate testosterone-to-DHT conversion:

Isoform Tissue Expression Primary Function Pharmacological Target
Type 1 Sebaceous glands, liver, skin, brain Contributes to acne, oily skin, and possibly some neurosteroid activity Finasteride has weak inhibition; dutasteride blocks both Type 1 and 2
Type 2 Prostate, seminal vesicles, scalp follicles, genital skin Drives prostate growth, male pattern baldness, and external genital development Target of finasteride (1 mg/day) and dutasteride (0.5 mg/day)

Type 2 is responsible for ~90% of DHT production in the prostate and scrotal skin. Its expression is regulated by androgen feedback loops, with increased activity observed in men with early-onset BPH. Type 1 plays a minor role in circulating DHT but influences sebum production and scalp DHT levels.

Genetic mutations in the SRD5A2 gene, which encodes Type 2 5-alpha reductase, cause 46,XY disorders of sex development. Affected individuals have undervirilized external genitalia at birth despite normal testicular testosterone production. This demonstrates that functional 5-alpha reductase is essential for full masculinization.

Where and Why the Conversion Occurs

DHT acts locally in tissues where 5-alpha reductase is expressed. In the scalp, DHT shrinks hair follicles over time through miniaturization, leading to thinning and eventual hair loss. This effect is most pronounced in genetically susceptible individuals whose follicles express high levels of androgen receptors.

In the prostate, DHT stimulates epithelial cell proliferation. Over decades, this contributes to benign prostatic hyperplasia (BPH), affecting nearly 50% of men over age 50. The Prostate Cancer Prevention Trial (PCPT) found that men taking finasteride (a Type 2 inhibitor) had a 25% lower risk of developing BPH over four years, though they experienced a slight increase in high-grade cancer incidence.

During fetal development, DHT is critical for the formation of the penis, scrotum, and prostate. Without adequate 5-alpha reductase activity, male fetuses may develop ambiguous genitalia. This condition, known as 5-alpha reductase deficiency, results in individuals assigned male at birth who appear female at birth but develop male secondary sex characteristics at puberty.

Common Misconceptions and Clarifications

Many assume that elevated DHT causes muscle gain or improved athletic performance. However, DHT does not improve anabolic effects beyond testosterone. In fact, DHT suppresses luteinizing hormone (LH) release via negative feedback, potentially reducing endogenous testosterone production in long-term users of DHT-based compounds.

Another misconception is that all DHT comes from testosterone. While testosterone is the primary precursor, trace amounts of DHT can form from dehydroepiandrosterone (DHEA) via alternative pathways. These contribute less than 5% of total DHT in healthy adults and are not clinically significant.

DHT is not a direct product of adrenal androgens. The adrenal cortex produces DHEA and androstenedione, which can be converted to testosterone in peripheral tissues. Only after testosterone formation does 5-alpha reductase act. Thus, adrenal androgen excess (e.g., in congenital adrenal hyperplasia) does not directly increase DHT unless testosterone is available.

Real-World Application: A Case Study

A 42-year-old man presented with progressive hair thinning and a 2 cm prostate nodule detected on digital rectal exam. Serum testosterone was 520 ng/dL, free testosterone 52 pg/mL, and DHT 120 ng/dL. His DHT-to-testosterone ratio was 0.23, above the typical threshold of 0.15.

He was diagnosed with early-stage BPH and androgenetic alopecia. After six months on finasteride 1 mg daily, his DHT dropped to 58 ng/dL, hair shedding decreased by 60%, and prostate volume reduced from 42 mL to 35 mL. His PSA remained stable at 2.1 ng/mL, consistent with treatment response.

This case illustrates that inhibiting 5-alpha reductase reduces DHT-driven pathology in both the scalp and prostate. The patient reported mild erectile dysfunction (grade 1 on the IIEF-5 scale), a known side effect of finasteride, but no gynecomastia or mood changes.

Final Note


Related Posts